The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
626
Immunotherapy with allogeneic prostate vaccine
Chemotherapy (Taxotere and prednisone)
Survival
Time frame: 0
Bone pain and bone related events
Time frame: 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Central Alabama Oncology, LLC
Alabaster, Alabama, United States
Alaska Clinical Research Center
Anchorage, Alaska, United States
Palo Verde Hematology/Oncology
Glendale, Arizona, United States
Mayo Clinic Scottsdale
Scottsdale, Arizona, United States
ACRC/Arizona Clinical Res. Ctr. Inc.
Tuscon, Arizona, United States
Arkansas Cancer Research Center
Little Rock, Arkansas, United States
Compassionate Cancer Care Medical Group, Inc.
Corona, California, United States
Pacific Coast Hem Onc. Medical Group
Fountain Valley, California, United States
California Cancer Care
Greenbrae, California, United States
Center for Urological Research
La Mesa, California, United States
...and 116 more locations